Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study - Quiz - MDSpire

Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study

  • By

  • Zimu Gong

  • Godsfavour Umoru

  • Jorge Monge

  • Nishi Shah

  • Ghulam Rehman Mohyuddin

  • Sabarinath Venniyil Radhakrishnan

  • Rajshekhar Chakraborty

  • Leo Rasche

  • Carolina Schinke

  • Anita D’Souza

  • Meera Mohan

  • March 5, 2024

  • 0 min

Share

Original Source(s)

Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study

  • by Zimu Gong, Godsfavour Umoru, Jorge Monge, Nishi Shah, Ghulam Rehman Mohyuddin, Sabarinath Venniyil Radhakrishnan, Rajshekhar Chakraborty, Leo Rasche, Carolina Schinke, Anita D’Souza, Meera Mohan

  • March 5, 2024

Related Content

This Week’s Biopharma News: Amgen Deepens US Manufacturing Push

The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production

  • May 12, 2026

  • 7 min
Enterocolitis Associated with Immune Effector Cells Following BCMA-Targeted CAR T-Cell Therapy: Findings from a Multicenter Case Series

Combination of Lisaftoclax, Ixazomib, and Dexamethasone for Maintenance Therapy Following CAR-T in Patients with Transplant-Ineligible Relapsed/Refractory Ultra-High-Risk Multiple Myeloma: A Review of Two Cases and Relevant Literature